Figure 2
Figure 2. Assessment of colony forming cells (CFC) in control and FPD/AML patient CD34+CD38+ cells. CD34+CD38+ cells from peripheral blood of FPD/AML patients with R174Q (AII-1, AII-2), or R139X (BII-2, BIII-1) RUNX1 mutation, and from peripheral blood of different healthy individuals (C) were plated in methylcellulose. Progenitor content (BFU-E, CFU-GM, and CFU-GEMM) was determined at 2 weeks of culture. The number of colonies was expressed per 1 × 103 of plated CD34+ cells.

Assessment of colony forming cells (CFC) in control and FPD/AML patient CD34+CD38+ cells. CD34+CD38+ cells from peripheral blood of FPD/AML patients with R174Q (AII-1, AII-2), or R139X (BII-2, BIII-1) RUNX1 mutation, and from peripheral blood of different healthy individuals (C) were plated in methylcellulose. Progenitor content (BFU-E, CFU-GM, and CFU-GEMM) was determined at 2 weeks of culture. The number of colonies was expressed per 1 × 103 of plated CD34+ cells.

Close Modal

or Create an Account

Close Modal
Close Modal